Biotech caught a bid Friday after Biogen announced positive results from a study on a drug aimed at treating early Alzheimer’s disease, its shares rose nearly 20 percent. The iShares Nasdaq Biotechnology ETF (IBB) surged 3.8 percent, bringing its YTD gains up to nearly 9 percent, outperformed the S&P by a wide margin. Now ...[read more]
↧